section name header

Pronunciation

am-FET-a-meen

Classifications

Therapeutic Classification: central nervous system stimulants

Indications

REMS


Action

  • Causes release of norepinephrine from nerve endings. Pharmacologic effects are:
    • CNS and respiratory stimulation,
    • Vasoconstriction,
    • Mydriasis (pupillary dilation).
Therapeutic effects:
  • Increased attention span in ADHD.
  • Increased motor activity, mental alertness, and decreased fatigue in narcolepsy.
  • Weight reduction.

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed in body tissues, with high concentrations in the brain and CSF.

Metabolism/Excretion: Some metabolism by the liver. Urinary excretion is pH-dependent. Alkaline urine promotes reabsorption and prolongs action.

Half-Life: 10–15 hr.

Time/Action Profile

(CNS stimulation)

ROUTEONSETPEAKDURATION
PO1–2 hrunknown4–10 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypertension, palpitations, tachycardia, cardiomyopathy ( with prolonged use, high doses), hypotension, peripheral vasculopathy, SUDDEN DEATH

Derm: urticaria

Endo: growth inhibition (with long term use in children)

GI: anorexia, constipation, diarrhea, cramps, dry mouth, intestinal ischemia, metallic taste, nausea, vomiting

GU: erectile dysfunction, libido

Neuro: hyperactivity, insomnia, restlessness, tremor, dizziness, headache, irritability, tics, Tourette's syndrome

Misc: fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA), physical dependence, psychological dependence, tolerance

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Attention-Deficit/Hyperactivity Disorder

Narcolepsy

Obesity

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Adzenys ER, Adzenys-XR ODT, Dyanavel XR, Evekeo

Contr. Subst. Schedule

Schedule II (C-II)